214 related articles for article (PubMed ID: 30054307)
1. Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories.
Loghavi S; Sui D; Wei P; Garcia-Manero G; Pierce S; Routbort MJ; Jabbour EJ; Pemmaraju N; Kanagal-Shamanna R; Gur HD; Hu S; Zuo Z; Medeiros LJ; Kantarjian HM; Khoury JD
Blood Adv; 2018 Aug; 2(15):1807-1816. PubMed ID: 30054307
[TBL] [Abstract][Full Text] [Related]
2. Refined medullary blast and white blood cell count based classification of chronic myelomonocytic leukemias.
Schuler E; Schroeder M; Neukirchen J; Strupp C; Xicoy B; Kündgen A; Hildebrandt B; Haas R; Gattermann N; Germing U
Leuk Res; 2014 Dec; 38(12):1413-9. PubMed ID: 25444076
[TBL] [Abstract][Full Text] [Related]
3. [Clinical features of a new category, myelodysplastic/myeloproliferative diseases, defined by WHO classification].
Fukuhara T; Kakinoki Y
Rinsho Byori; 2006 Mar; 54(3):243-9. PubMed ID: 16637572
[TBL] [Abstract][Full Text] [Related]
4. Myelodysplastic and myeloproliferative type of chronic myelomonocytic leukemia--distinct subgroups or two stages of the same disease?
Voglová J; Chrobák L; Neuwirtová R; Malasková V; Straka L
Leuk Res; 2001 Jun; 25(6):493-9. PubMed ID: 11337023
[TBL] [Abstract][Full Text] [Related]
5. Chronic myelomonocytic leukemia: myelodysplastic or myeloproliferative?
Itzykson R; Fenaux P; Solary E
Best Pract Res Clin Haematol; 2013 Dec; 26(4):387-400. PubMed ID: 24507815
[TBL] [Abstract][Full Text] [Related]
6. Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia.
Such E; Germing U; Malcovati L; Cervera J; Kuendgen A; Della Porta MG; Nomdedeu B; Arenillas L; Luño E; Xicoy B; Amigo ML; Valcarcel D; Nachtkamp K; Ambaglio I; Hildebrandt B; Lorenzo I; Cazzola M; Sanz G
Blood; 2013 Apr; 121(15):3005-15. PubMed ID: 23372164
[TBL] [Abstract][Full Text] [Related]
7. Problems in the classification of CMML--dysplastic versus proliferative type.
Germing U; Gattermann N; Minning H; Heyll A; Aul C
Leuk Res; 1998 Oct; 22(10):871-8. PubMed ID: 9766745
[TBL] [Abstract][Full Text] [Related]
8. Comparison of three prognostic scoring systems in a series of 146 cases of chronic myelomonocytic leukemia (CMML): MD Anderson prognostic score (MDAPS), CMML-specific prognostic scoring system (CPSS) and Mayo prognostic model. A detailed review of prognostic factors in CMML.
Calvo X; Nomdedeu M; Santacruz R; Martínez N; Costa D; Pereira A; Estrada N; Xicoy B; Esteve J; Nomdedeu B
Leuk Res; 2015 Jul; ():. PubMed ID: 26354683
[TBL] [Abstract][Full Text] [Related]
9. [Clinical course, morphology and prognosis of chronic myelomonocytic leukemia].
Germing U; Strupp C; Meckenstock G; Giagounidis A; Minning H; Aul C
Med Klin (Munich); 1999 Sep; 94(9):467-72. PubMed ID: 10544608
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of SRSF2 mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia: a meta-analysis.
Arbab Jafari P; Ayatollahi H; Sadeghi R; Sheikhi M; Asghari A
Hematology; 2018 Dec; 23(10):778-784. PubMed ID: 29757120
[TBL] [Abstract][Full Text] [Related]
11. Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia.
Elena C; Gallì A; Such E; Meggendorfer M; Germing U; Rizzo E; Cervera J; Molteni E; Fasan A; Schuler E; Ambaglio I; Lopez-Pavia M; Zibellini S; Kuendgen A; Travaglino E; Sancho-Tello R; Catricalà S; Vicente AI; Haferlach T; Haferlach C; Sanz GF; Malcovati L; Cazzola M
Blood; 2016 Sep; 128(10):1408-17. PubMed ID: 27385790
[TBL] [Abstract][Full Text] [Related]
12. Dysplastic versus proliferative CMML--a retrospective analysis of 91 patients from a single institution.
Nösslinger T; Reisner R; Grüner H; Tüchler H; Nowotny H; Pittermann E; Pfeilstöcker M
Leuk Res; 2001 Sep; 25(9):741-7. PubMed ID: 11489467
[TBL] [Abstract][Full Text] [Related]
13. Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients.
Coston T; Pophali P; Vallapureddy R; Lasho TL; Finke CM; Ketterling RP; Carr R; Binder M; Mangaonkar AA; Gangat N; Al-Kali A; Litzow M; Zblewski D; Pardanani A; Tefferi A; Patnaik MM
Am J Hematol; 2019 Jul; 94(7):767-779. PubMed ID: 30964202
[TBL] [Abstract][Full Text] [Related]
14. Therapy for Chronic Myelomonocytic Leukemia in a New Era.
Moyo TK; Savona MR
Curr Hematol Malig Rep; 2017 Oct; 12(5):468-477. PubMed ID: 28983777
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of monocytosis in patients with myeloproliferative disorders.
Beran M; Shen Y; Onida F; Wen S; Kantarjian H; Estey E
Leuk Lymphoma; 2006 Mar; 47(3):417-23. PubMed ID: 16396764
[TBL] [Abstract][Full Text] [Related]
16. RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant.
Ricci C; Fermo E; Corti S; Molteni M; Faricciotti A; Cortelezzi A; Lambertenghi Deliliers G; Beran M; Onida F
Clin Cancer Res; 2010 Apr; 16(8):2246-56. PubMed ID: 20371679
[TBL] [Abstract][Full Text] [Related]
17. Mixed myeloproliferative and myelodysplastic disorders.
Emanuel PD
Curr Hematol Malig Rep; 2007 Feb; 2(1):9-12. PubMed ID: 20425383
[TBL] [Abstract][Full Text] [Related]
18. Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme.
van der Helm LH; Alhan C; Wijermans PW; van Marwijk Kooy M; Schaafsma R; Biemond BJ; Beeker A; Hoogendoorn M; van Rees BP; de Weerdt O; Wegman J; Libourel WJ; Luykx-de Bakker SA; Minnema MC; Brouwer RE; Croon-de Boer F; Eefting M; Jie KS; van de Loosdrecht AA; Koedam J; Veeger NJ; Vellenga E; Huls G
Br J Haematol; 2011 Dec; 155(5):599-606. PubMed ID: 21981697
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
Jain P; Kantarjian HM; Ghorab A; Sasaki K; Jabbour EJ; Nogueras Gonzalez G; Kanagal-Shamanna R; Issa GC; Garcia-Manero G; Kc D; Dellasala S; Pierce S; Konopleva M; Wierda WG; Verstovsek S; Daver NG; Kadia TM; Borthakur G; O'Brien S; Estrov Z; Ravandi F; Cortes JE
Cancer; 2017 Nov; 123(22):4391-4402. PubMed ID: 28743165
[TBL] [Abstract][Full Text] [Related]
20. Targeted deep sequencing improves outcome stratification in chronic myelomonocytic leukemia with low risk cytogenetic features.
Palomo L; Garcia O; Arnan M; Xicoy B; Fuster F; Cabezón M; Coll R; Ademà V; Grau J; Jiménez MJ; Pomares H; Marcé S; Mallo M; Millá F; Alonso E; Sureda A; Gallardo D; Feliu E; Ribera JM; Solé F; Zamora L
Oncotarget; 2016 Aug; 7(35):57021-57035. PubMed ID: 27486981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
